Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
复制标题
DOI：
10.1186/s12879-022-07239-z
复制
发表时间：
2022-03-20
影响因子：
3.7
通讯作者：
Sharkey KJ
中科院分区：
文献类型：
--
作者：
Pattni K;Hungerford D;Adams S;Buchan I;Cheyne CP;García-Fiñana M;Hall I;Hughes DM;Overton CE;Zhang X;Sharkey KJ
从2021年1月到5月，SARS-CoV-2的α变体（B.1.1.7）是英国最常见的变体。此后，Delta变体（B.1.617.2）成为主要变体。英国COVID-19疫苗接种计划于二零二零年十二月八日开始。在Delta变体之前，大多数疫苗有效性研究都集中在Alpha变体上。因此，我们旨在评估BNT 162 b2（Pfizer-BioNTech）和ChAdOx 1 nCoV-19（Oxford-AstraZeneca）疫苗在英国环境中预防Delta变异体的症状性和无症状性感染的有效性。我们使用了与感染数据（PCR）相关的匿名公共卫生记录数据，这些数据使用了人口健康行动综合情报资源。然后，我们构建了一个SIR流行病模型来解释英国柴郡和默西塞德郡地区的SARS-CoV-2感染数据。假设疫苗在21天后（1剂）和14天后（2剂）有效。我们确定牛津-阿斯利康疫苗在降低感染易感性方面的有效性，单剂量和双剂量分别为39%（95%可信区间[34，43]）和64%（95%可信区间[61，67]）。对于Pfizer-BioNTech疫苗，单剂量和双剂量的有效性分别为20%（95%可信区间[10，28]）和84%（95%可信区间[82，86]）。在接受两剂疫苗后，降低SARS-CoV-2感染易感性的疫苗有效性显示出明显的改善。研究结果还表明，Pfizer-BioNTech的整个疗程可以提供最佳的保护，防止感染Delta变体。这就更加需要完成整个课程，以最大限度地保护个人和减少传播。在线版本包含补充材料，可通过10.1186/s12879-022-07239-z获得。
From January to May 2021 the alpha variant (B.1.1.7) of SARS-CoV-2 was the most commonly detected variant in the UK. Following this, the Delta variant (B.1.617.2) then became the predominant variant. The UK COVID-19 vaccination programme started on 8th December 2020. Prior to the Delta variant, most vaccine effectiveness studies focused on the alpha variant. We therefore aimed to estimate the effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines in preventing symptomatic and asymptomatic infection with respect to the Delta variant in a UK setting. We used anonymised public health record data linked to infection data (PCR) using the Combined Intelligence for Population Health Action resource. We then constructed an SIR epidemic model to explain SARS-CoV-2 infection data across the Cheshire and Merseyside region of the UK. Vaccines were assumed to be effective after 21 days for 1 dose and 14 days for 2 doses. We determined that the effectiveness of the Oxford-AstraZeneca vaccine in reducing susceptibility to infection is 39% (95% credible interval [34, 43]) and 64% (95% credible interval [61, 67]) for a single dose and a double dose respectively. For the Pfizer-BioNTech vaccine, the effectiveness is 20% (95% credible interval [10, 28]) and 84% (95% credible interval [82, 86]) for a single-dose and a double dose respectively. Vaccine effectiveness for reducing susceptibility to SARS-CoV-2 infection shows noticeable improvement after receiving two doses of either vaccine. Findings also suggest that a full course of the Pfizer-BioNTech provides the optimal protection against infection with the Delta variant. This reinforces the need to complete the full course programme to maximise individual protection and reduce transmission. The online version contains supplementary material available at 10.1186/s12879-022-07239-z.
登录
查看更多内容
DOI：
10.1016/s0140-6736(20)32661-1
发表时间：
2021-01-09
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Clemens SAC;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Collins AM;Colin-Jones R;Cutland CL;Darton TC;Dheda K;Duncan CJA;Emary KRW;Ewer KJ;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Goodman AL;Green CM;Green CA;Heath PT;Hill C;Hill H;Hirsch I;Hodgson SHC;Izu A;Jackson S;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Lawrie AM;Lelliott A;Libri V;Lillie PJ;Mallory R;Mendes AVA;Milan EP;Minassian AM;McGregor A;Morrison H;Mujadidi YF;Nana A;O'Reilly PJ;Padayachee SD;Pittella A;Plested E;Pollock KM;Ramasamy MN;Rhead S;Schwarzbold AV;Singh N;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Tarrant R;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;Watson MEE;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
7.7
作者：
Tindale, Lauren C.;Stockdale, Jessica E.;Colijn, Caroline
通讯作者：
Colijn, Caroline
影响因子：
11.7
作者：
Lau, H.;Khosrawipour, T.;Khosrawipour, V
通讯作者：
Khosrawipour, V
影响因子：
1.9
作者：
Brereton, Claire;Pedercini, Matteo
通讯作者：
Pedercini, Matteo